AMPICILLIN SODIUM

Post-LOE

ampicillin sodium

Novartis

ANDAINJECTIONINJECTABLE1 Generic Approved

Approved

Mar 1971

Lifecycle

Post-LOE

Competitive Pressure

45/100

Data completeness

3/8 — Basic

AMPICILLIN SODIUM (ampicillin sodium) by Novartis is clinical pharmacology ampicillin for injection diffuses readily into most body tissues and fluids. Approved for the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: respiratory tract infections caused by streptococcus pneumoniae. First approved in 1971.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Ampicillin for injection diffuses readily into most body tissues and fluids. However, penetration into the cerebrospinal fluid and brain occurs only when the meninges are inflamed. Ampicillin is excreted largely unchanged in the urine and its excretion can be delayed by…

Indications (1)

Worked on AMPICILLIN SODIUM at Novartis? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.